Healthcare >> CEO Interviews >> November 17, 2008
RICHARD B. BREWER, President and Chief Executive Officer of ARCA biopharma,
Inc., has more than 30 years of experience in the biotechnology industry,
developing and commercializing drugs for major unmet medical needs, particularly
in heart disease. Prior to joining ARCA, Mr. Brewer was managing partner of
Crest Asset Management, providing guidance to and investing in biotechnology
opportunities. Before that, Mr. Brewer was President and CEO of Scios, Inc.,
where he led the successful approval and launch of Natrecor(r) (nesiritide), the
first new drug for acute heart failure in more than a decade, and guided Scios
through a $2.4 billion merger with Johnson and Johnson. Before Scios, Mr. Brewer
served as Chief Operating Officer of Heartport, a cardiovascular device company
developing minimally invasive approaches to major heart surgery. Prior to that,
he spent over a decade at Genentech in various management positions, including
Senior Vice President of Sales and Marketing and Senior Vice President of
Genentech Europe and Canada. Mr. Brewer holds a BS from Virginia Polytechnic
Institute and an MBA from Northwestern University. Profile
MR. Brewer: Yes, I would be happy to. Arca Biopharma was founded in 2004 by Dr.
Michael Bristow and Chris Ozeroff in
